Treatment Outcomes of Elderly Patients with Mantle Cell Lymphoma: A Multi-center Real-World Data
Authors:
- Ebru Kilic GunesEGEbru Kilic Gunes
- Filiz YavasogluFYFiliz Yavasoglu
- Selin KucukyurtSKSelin Kucukyurt
- Fatma AykasFAFatma Aykas
- Sureyya Yigit KayaSKSureyya Yigit Kaya
- Munevver Irem Kok YilmazMYMunevver Irem Kok Yilmaz
- Murat YildirimMYMurat Yildirim
- Neslihan AndicNANeslihan Andic
- Ahmet Kursad GunesAGAhmet Kursad Gunes
- Volkan KarakusVKVolkan Karakus
- Omur Gokmen SevindikOSOmur Gokmen Sevindik
- Zubeyde Nur OzkurtZOZubeyde Nur Ozkurt
- 12 February 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 82-92
Abstract
Mantle Cell Lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for 5–7% of all lymphomas. Currently, there is no standardized treatment option for older patients (> 65 years), and optimizing MCL treatment in this group remains a significant clinical challenge. In this multicenter retrospective study, we aimed to evaluate the outcomes of first-line treatments, overall survival (OS), progression-free survival (PFS), and factors influencing survival in patients aged 65 years and older diagnosed with MCL. Patients aged ≥ 65 years diagnosed with MCL between November 2016 and January 2024 in six centers were included in this study. A total of 77 patients were included in the study, with 60 males (77.9%) and 17 females (22.1%). The median age was 71 years (range: 65–89). At diagnosis, 96.1% of patients had Stage III-IV disease, and 36.4% had an ECOG performance score of 2–3. Based on the MIPI-c score, 48% of patients had high-risk disease. As induction chemotherapy, 44.2% received R-CHOP, 13% received RB, 13% received R-CVP, and 29.8% received alternating R-CHOP/R-DHA-platinum. Additionally, 19.5% of patients underwent ASCT, and 28.6% received Rituximab maintenance after induction therapy or ASCT. The overall response rate (ORR) was 71.4%. After a median follow-up of 32 months, the median PFS was 18 months, and the median OS was 42 months. In multivariate analysis, independent risk factors for inferior PFS were LDH > ULN (HR: 2.09, 95% CI: 1.05–4.16, p = 0.035), Ki67 ≥ 30% (HR: 2.90, 95% CI: 1.38–6.10, p = 0.005), blastoid variant (HR: 1.86, 95% CI: 1.09–5.12, p = 0.040), and maintenance treatment (HR: 0.31, 95% CI: 0.12–0.75, p = 0.010). Independent risk factors for inferior OS were the maintenance treatment (HR: 0.29, 95% CI: 0.09–0.94, p = 0.040) and POD24 (HR: 2.04, 95% CI: 1.06–4.19, p = 0.044). There remains no universally accepted standard treatment for older MCL patients, and the disease remains incurable with current treatment modalities. However, advancements in targeted therapies and the optimization of maintenance strategies hold promise for improving survival in older and unfit patients. Future studies focusing on incorporating targeted therapies into first-line treatment and identifying high-risk factors that influence survival will be crucial in tailoring effective and individualized treatment approaches for this population.Keywords
This publication has 35 references indexed in Scilit:
- Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysisCancer Medicine, 2023
- Mantle-Cell LymphomaNew England Journal of Medicine, 2022
- Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaNew England Journal of Medicine, 2022
- Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular LymphomaClinical Lymphoma Myeloma and Leukemia, 2020
- Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study GroupeJHaem, 2020
- Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphomaScientific Reports, 2019
- Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiThe Lancet Haematology, 2017
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL NetworkJournal of Hematopathology, 2009
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009